Girao Tiago 4

What Happened
Tiago Girao, Chief Financial Officer of Immunovant, sold 25,760 shares (reported as a sale) on April 23, 2026, for a weighted-average price of $29.62 per share, generating proceeds of approximately $763,011. This was a sell-to-cover transaction tied to the vesting and settlement of previously granted RSUs and not a discretionary open-market sale.

Key Details

• Transaction date: 2026-04-23; Form 4 filed: 2026-04-24 (timely filing).
• Shares sold: 25,760; weighted-average price: $29.62; total proceeds: ~$763,011.
• Price range: $29.23–$30.00 per share (sale occurred in multiple trades; reporting person will provide per-price breakdown upon request).
• Shares owned after transaction: Not specified in the filing.
• Footnote: On May 1, 2025 the reporting person was granted 208,388 RSUs; 52,097 vested on April 21, 2026. The sale was mandated by the issuer’s sell-to-cover election to satisfy tax withholding and was not a discretionary sale by the reporting person.

Context
Sell-to-cover transactions are a common, administrative step when restricted stock units vest and taxes are due; they generally reflect tax withholding needs rather than a judgment about the company's prospects.